Get To Know

Mark Saltzman

PhD Yale School of Medicine

W. Mark Saltzman is an engineer and educator. His research, which has affected the fields of drug delivery, biomaterials, nanobiotechnology, and tissue engineering, is described in more than 300 research papers and patents. He is also the sole author of three textbooks: Biomedical Engineering, Tissue Engineering, and Drug Delivery.
Dr. Saltzman graduated from Iowa State University with a BS in chemical engineering and received graduate degrees in chemical engineering and medical engineering from MIT. He has served as a faculty member at Johns Hopkins University, Cornell University, and Yale University. Dr. Saltzman was appointed the Goizueta Foundation Professor of Chemical and Biomedical Engineering at Yale in 2002. He was the founding chair of Yale’s Department of Biomedical Engineering and served in that role for 12 years.
Dr. Saltzman has been recognized for excellence in research and teaching: Camille and Henry Dreyfus Foundation Teacher-Scholar Award; the Allan C. Davis Medal as Maryland’s Outstanding Young Engineer; the Controlled Release Society’s Young Investigator Award and Founders Award; and the Professional Progress in Engineering and Professional Achievement Citation in Engineering Awards from Iowa State University. He has been elected a Fellow of the American Institute for Medical and Biological Engineering; a Fellow of the Biomedical Engineering Society; a Member of the Connecticut Academy of Science & Engineering; a Fellow of the National Academy of Inventors; and an elected member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering. He has delivered over 300 invited lectures throughout the world.
In addition to his academic work, Dr. Saltzman has been active as an innovator. He is a co-founder of Stradefy Biosciences, Xanadu Biosciences and B3 Biosciences, which are currently operating in New Haven. He is a consultant or advisory board member with two small pharma ventures and two major pharma companies. Over the past years, he has collaborated on research projects with leading biotechnology and medical device companies.